Praxis Precision Medicines Quarterly Income Statement
NASDAQ: PRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
259.86-3.69 (-1.40%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Praxis Precision Medicines revenue and earnings
Praxis Precision Medicines reported a net loss of $83.7 million, compared with a loss of $71.1 million a year earlier. Diluted earnings per share came in at -$2.87.
Summary generated from market data by MetaCap's automated system. Methodology
Praxis Precision Medicines income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 7.46M | 302.00K | 357.00K | 431.00K | 515.00K | 468.00K |
| Revenue growth (YoY) | — | — | -100.00% | -100.00% | -100.00% | -100.00% | +1349.13% | -35.47% | -54.29% | -36.90% | — | — |
| Operating Expenses | 96.90M | 105.86M | 97.04M | 78.36M | 76.07M | 74.73M | 71.42M | 57.14M | 37.84M | 42.32M | 28.32M | 25.98M |
| Research & Development | 69.42M | 77.99M | 77.51M | 65.80M | 63.01M | 60.81M | 56.29M | 41.88M | 27.26M | 26.98M | 18.39M | 17.26M |
| Operating Income | -96.90M | -105.86M | -97.04M | -78.36M | -76.07M | -74.73M | -63.96M | -56.84M | -37.49M | -41.89M | -27.81M | -25.52M |
| Other Income (Expense) | 13.18M | 13.30M | 8.13M | 4.42M | 4.94M | 5.43M | 5.28M | 4.92M | 4.81M | 2.33M | 928.00K | 884.00K |
| Net Income | -83.72M | -92.56M | -88.91M | -73.93M | -71.13M | -69.30M | -58.68M | -51.91M | -32.68M | -39.55M | -26.88M | -24.63M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -2.87 | -3.20 | -3.52 | -3.36 | -3.31 | -3.29 | -2.88 | -2.75 | -1.74 | -2.84 | 1.99 | -2.72 |
| EPS (Diluted) | -2.87 | -3.20 | -3.52 | -3.36 | -3.31 | -3.29 | -2.88 | -2.75 | -1.74 | -2.84 | 1.99 | -2.72 |
| Shares Outstanding (Basic) | 29.13M | 28.88M | — | 21.98M | 21.47M | 21.06M | — | 18.88M | 18.82M | 13.90M | — | 9.04M |
| Shares Outstanding (Diluted) | 29.13M | 28.88M | — | 21.98M | 21.47M | 21.06M | — | 18.88M | 18.82M | 13.90M | — | 9.04M |
| EBITDA | -96.87M | -105.82M | -97.02M | -78.34M | -76.02M | -74.68M | -63.91M | -56.74M | -37.38M | -41.77M | -27.70M | -25.41M |
| Operating Margin | — | — | — | — | — | — | -856.97% | -18819.54% | -10500.84% | -9718.33% | -5399.22% | -5452.14% |
| Net Margin | — | — | — | — | — | — | -786.27% | -17188.74% | -9153.22% | -9177.03% | -5219.03% | -5263.25% |
This table shows 12 quarterly periods of Praxis Precision Medicines's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PRAX's reporting calendar. What is a income statement?